Mizuho reiterated their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research report sent to investors on Thursday morning, AnalystRatings.com reports. Mizuho currently has a $7.00 target price on the stock.
CRVS has been the topic of several other research reports. Zacks Investment Research downgraded Corvus Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, July 13th. ValuEngine upgraded Corvus Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, April 2nd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Corvus Pharmaceuticals has an average rating of Buy and a consensus price target of $7.25.
NASDAQ:CRVS opened at $4.24 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.96 and a current ratio of 5.96. Corvus Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $6.88. The company has a fifty day moving average of $3.60 and a two-hundred day moving average of $3.54.
In related news, major shareholder Holdings A/S Novo sold 1,538,062 shares of the stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $5.31, for a total value of $8,167,109.22. Following the completion of the sale, the insider now owns 2,130,938 shares of the company’s stock, valued at $11,315,280.78. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 45.12% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in CRVS. Squarepoint Ops LLC purchased a new stake in shares of Corvus Pharmaceuticals in the first quarter valued at about $52,000. Two Sigma Advisers LP grew its stake in shares of Corvus Pharmaceuticals by 74.2% in the 1st quarter. Two Sigma Advisers LP now owns 28,880 shares of the company’s stock valued at $61,000 after buying an additional 12,300 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Corvus Pharmaceuticals during the 1st quarter worth approximately $63,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Corvus Pharmaceuticals by 4.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 85,604 shares of the company’s stock valued at $181,000 after buying an additional 3,804 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Corvus Pharmaceuticals by 79.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 107,176 shares of the company’s stock valued at $583,000 after acquiring an additional 47,293 shares during the last quarter. 73.89% of the stock is currently owned by hedge funds and other institutional investors.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Read More: Index Funds
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.